-+ 0.00%
-+ 0.00%
-+ 0.00%

Abivax says FDA pre-NDA talks support obefazimod ulcerative colitis filing plan

PUBT·07/30/2026 20:17:22
Listen to the news
Abivax says FDA pre-NDA talks support obefazimod ulcerative colitis filing plan
  • Abivax secured FDA alignment in a pre-NDA interaction for obefazimod in moderately to severely active ulcerative colitis.
  • The company kept its target to file its first U.S. New Drug Application by end-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2374888_en) on July 30, 2026, and is solely responsible for the information contained therein.